Placebo atorvastatin

DRUG3 trials

Sponsors

Laura Schanberg, Dr. med. Mahir Karakas, Centro Cardiologico Monzino

Conditions

Acute Chest SyndromeArrhythmogenic CardiomyopathyLupus Erythematosus, Systemic

Phase 2

Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH)

RecruitingNCT06922994

Centro Cardiologico MonzinoArrhythmogenic Cardiomyopathy

Start: 2025-03-31End: 2026-11-30Target: 102Updated: 2025-07-03

Phase 3

Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)

CompletedNCT00065806

Laura SchanbergLupus Erythematosus, Systemic

Start: 2003-09-30End: 2009-12-31Updated: 2013-08-15

Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin

TerminatedNCT03820466

Dr. med. Mahir KarakasAcute Chest Syndrome

Start: 2020-02-21End: 2022-04-07Updated: 2022-05-24

Related Papers

Statin effect on arrhythmogenic cardiomyopathy disease progression (SEARCH): Randomized clinical study protocol

PLoS ONE2025-09-29

SPIRIT Outcome checklist [53].

OPAL (Open@LaTrobe) (La Trobe University)2025-09-29

SEARCH protocol.

OPAL (Open@LaTrobe) (La Trobe University)2025-09-29

Avascular necrosis in pediatric systemic lupus erythematosus: a brief report and review of the literature.

2015-04-2317 citations

Vitamin D status is a determinant of atorvastatin effect on carotid intima medial thickening progression rate in children with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) substudy

Lupus Science & Medicine2014-09-0124 citations

Vitamin D deficiency is common and associated with increased C-reactive protein in children and young adults with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus substudy

Lupus Science & Medicine2014-04-0138 citations

Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.

2013-02-2250 citations